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Abstract
Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of 
relapsed or refractory multiple myeloma (RRMM). It is possible that single- agent 
Len may be effective as prolonged treatment regimen in RRMM once patients 
demonstrate an initial response to Len+Dex induction. Patients with RRMM who 
responded to first- line Len+Dex in an observational study (NCT01430546) received 
up to 24 cycles of either Len (25 mg/day) or Len+Dex (25 mg/day and 40 mg/
week) as prolonged treatment in a subsequent phase 2 clinical trial (NCT01450215). 
In the observational study (N = 133), median time to response was 1.7 (range 
0.6–9.6) months. A complete response to all treatments received in both studies 
was observed in 11% of patients; very good partial response and partial response 
rates were 31% and 38%, respectively. Corresponding response rates in the subgroup 
of patients who did not enter the phase 2 trial (n = 71) were 3%, 18%, and 39%, 
respectively. Rates of disease progression at 2 years in the phase 2 trial were 47% 
versus 31% for Len versus Len+Dex (P = 0.14). After 36 months median follow- up 
in surviving patients, median time to progression was not reached with Len+Dex 
and was 24.9 months (95% confidence interval 12.5–not calculable, P < 0.001) with 
Len. Three- year OS among the total observational study population was 61% (95% 
CI, 52–69%). The corresponding rate among patients who entered the phase 2 
clinical trial was 73% (95% CI, 60–83%) and was significantly lower among those 
patients who achieved ≥PR but did not proceed into the phase 2 trial (55%; P = 0.01). 
In the phase 2 trial, OS was 73% in both treatment arms (P = 0.70). Neutropenia 
and thrombocytopenia were more common with prolonged (phase 2 trial) versus 
short- term (observational study) Len administration but remained manageable. 
Prolonged treatment with Len with or without Dex provides sustained, clinically 
relevant responses and demonstrates an acceptable safety profile.
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Research in context
Evidence before these studies
Therapeutic advances in recent years have significantly 
prolonged survival in patients with multiple myeloma 
(MM); nevertheless, almost all patients eventually relapse 
following first- line treatment. In Europe, combination 
treatment with the immunomodulatory drug lenalidomide 
(Len) plus the glucocorticoid dexamethasone (Dex) is the 
standard of care for patients experiencing a first relapse. 
However, no studies published before the present research 
were undertaken reported rates of response to this regi-
men in patients who had received only one prior line of 
therapy.
Lenalidomide exerts its antimyeloma effects via a two- 
pronged mechanism of action: It directly induces tumor 
cell death, while also stimulating the immune response 
to prevent disease recurrence. In vitro data demonstrate 
that although dexamethasone enhances the antiproliferative 
effects of lenalidomide when administered concomitantly, 
it simultaneously inhibits the drug’s immunomodulatory 
properties in a dose- dependent manner. It is possible that 
once patients achieve an initial response to treatment and 
the need for tumoricidal efficacy decreases, dexamethasone 
could be omitted from the treatment regimen to minimize 
glucocorticoid- induced immunosuppression, and long- 
term treatment continued with single- agent lenalidomide. 
Studies have confirmed the efficacy of single- agent lena-
lidomide as maintenance therapy in newly diagnosed 
myeloma, but data in the relapsed or refractory setting 
were previously lacking.
Added value of these studies
The findings of our observational study confirm the value 
of Len+Dex as a first- line treatment for RRMM, providing 
further evidence of the efficacy of this combination when 
administered to patients with MM at first relapse. The 
phase 2 trial results demonstrate, for the first time, that 
single- agent Len yields similar survival benefits to Len+Dex 
when used in the prolonged setting in RRMM; they also 
add to the growing body of evidence indicating that con-
tinuous Len+Dex improves outcomes versus fixed- duration 
therapy.
Implications of all the available evidence
Our findings, taken in combination with those in previ-
ously published reports, support the positioning of 
Len+Dex as a first- line treatment for patients with RRMM. 
Single- agent Len is already established as prolonged treat-
ment in newly diagnosed MM; we now provide evidence 
to suggest that prolonged treatment with single- agent Len 
may also be an option for patients with RRMM, poten-
tially providing similar survival benefits to those observed 
with Len+Dex.
Introduction
The introduction of proteasome inhibitors (PIs) and 
immunomodulatory drugs has significantly prolonged sur-
vival for patients with multiple myeloma (MM) over the 
past 15 years [1, 2]. The immunomodulatory drug lena-
lidomide (Len) has an established efficacy and safety profile 
in the treatment of MM [3, 4] and is approved in this 
indication in combination with dexamethasone (Dex) [5]. 
The approval of Len for the treatment of relapsed or 
refractory MM (RRMM) was largely based on the results 
of two phase 3 trials [6, 7]. A preplanned subset analysis 
of data from these trials found that Len+Dex administered 
at first relapse significantly prolonged median time to 
progression (TTP) in patients who had received only 1 
versus ≥2 prior therapies (17.1 months vs. 10.6 months) 
[8]. The complete response (CR) plus very good partial 
response (VGPR) rate was also significantly higher in 
patients experiencing first versus later relapse (39.8% vs. 
27.7%). These findings suggest that Len+Dex is most 
beneficial in RRMM when administered early.
It is possible that once patients have achieved a response 
with Len+Dex, the need for tumoricidal effects subsides 
and the immunostimulatory effect of Len becomes of 
greater importance for the control of myeloma cells and, 
thus, disease progression. Potentially, Dex could be reduced 
or omitted to minimize glucocorticoid- induced immuno-
suppression. A meta- analysis of the results of three ran-
domized, placebo- controlled trials confirmed that 
single- agent Len, administered as maintenance therapy in 
newly diagnosed MM following induction and consolida-
tion treatment, prolonged both progression-free survival (PFS) 
and overall survival (OS) versus placebo [9–12]. We therefore 
compared single- agent Len versus Len+Dex as prolonged 
therapy for patients with RRMM who achieved at least 
a partial response (PR) following initial Len+Dex treat-
ment at first relapse.
Methods
Study design and participants
Two studies were conducted in Denmark, Norway, and 
Sweden by the Nordic Myeloma Study Group. The study 
protocols were approved by the local ethics committee 
in Stockholm, Sweden. All patients provided written 
informed consent, and all procedures were conducted in 
accordance with the Declaration of Helsinki, the 
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International Conference on Harmonization, and 
Guidelines for Good Clinical Practice.
Observational study
The first study was a multicentre, observational, nonin-
terventional study (ClinicalTrials.gov registration number 
NCT01430546; protocol available online) in Len- naïve 
patients with RRMM who were experiencing a first relapse. 
Relapse was defined as chemical relapse with no demands 
on CRAB criteria. Inclusion criteria included age ≥18 years 
and a diagnosis of MM confirmed by serum M- protein 
>0.5 g/dL or urinary Bence Jones protein >200 mg/24 h. 
Patients with plasma cell leukemia, nonhematologic malig-
nancies (except cancers of the skin, thyroid, cervix, breast, 
or prostate [Gleason grade ≤6], and cancers considered 
to be cured), or amyloidosis were excluded. Patients 
received Len 25 mg orally on days 1–21, and Dex 40 mg 
orally on days 1, 8, 15, and 22, of each 28- day cycle. 
Each patient completed ≤9 treatment cycles, with clinic 
visits scheduled at the beginning of each cycle. Data were 
collected at each visit via questionnaires about symptoms 
and treatment side effects. All serious adverse events (SAEs) 
occurring from consent form signature until 30 days after 
the last dose of study drug or initiation of new anticancer 
therapy (whichever occurred first) were reported. Adverse 
events (AEs) and SAEs were documented using Medical 
Dictionary for Regulatory Activities (MedDRA) classifica-
tion. Health- related quality of life (HRQoL) was measured 
before the start of treatment, at 3 and 6 months, and 
1 month after the end of treatment. Patients achieving 
≥PR received two further cycles of Len+Dex consolidation 
with unmodified dose and were invited to join a prospec-
tive, randomized, open- label, multicentre, phase 2 clinical 
trial (ClinicalTrials.gov registration number NCT01450215; 
protocol available online). No time elapsed from complet-
ing the phase 4 trial to enrollment in the phase 2 trial; 
all patients were on continuous treatment. Reasons for 
patients participated in the phase 4 trial to not take part 
in the randomized phase 2 trial were death (n = 3), 
adverse events (n = 20), progressive disease (n = 21), no 
response (n = 11), withdrawn consent (n = 1), problems 
with compliance (n = 1), and withdrawn consent (n = 1). 
The rest (n = 13) completed the nine planned cycles and 
did not want to take part in the randomized study. The 
median number of cycles in phase 4 study was four cycles 
(0.3–28).
Among patients who achieved ≥PR but did not par-
ticipate in the phase 2 trial, reasons for nonparticipation 
were as follows: patient refusal to participate; AEs resulting 
in study drug dose modification or discontinuation; and 
disease progression before being invited to participate in 
the phase 2 trial. Observational study participants who 
did not enter the phase 2 trial received ≤9 cycles of 
Len+Dex and no further treatment thereafter.
Phase 2 clinical trial
Randomization
Phase 2 trial participants were randomized (fixed block 
1:1) to prolonged treatment with either single- agent Len 
or combined Len+Dex. Randomization was performed at 
the Hematology Center at Karolinska University Hospital, 
Sweden, using a central computer- generated, Microsoft 
Excel- based randomization system designed by the study 
statistician. When the study nurse entered information 
from a patient’s consent form into the system, the pro-
gram randomly allocated the patient to a treatment arm.
Procedures
Patients received either Len or Len+Dex for ≤24 cycles 
of 28 days’ duration. Patients in both treatment groups 
received Len 25 mg/day orally on days 1–21 of each 
cycle. Len+Dex patients also received Dex 40 mg orally 
on days 1, 8, 15, and 22 of each cycle. Clinic visits were 
scheduled at the beginning of each cycle. Data were col-
lected at each visit via questionnaires about symptoms 
and treatment side effects. Depths of responses (PR, VGPR, 
or CR) were evaluated in comparison with M- protein 
levels prior to entry in the observational study. All SAEs 
occurring from consent form signature until 30 days after 
the last dose of study drug or initiation of new anticancer 
therapy (whichever occurred first) were reported. After 
completion of 24 cycles, no further treatment was planned.
Analysis of chromosomal abnormalities by 
fluorescent in situ hybridization
Chromosomal abnormalities were analyzed by fluorescence 
in situ hybridization (FISH). Briefly, CD138+ plasma cells 
(2–4 × 104 cells/spot) were centrifuged to prepare hybridi-
zation slides using Cytospin (Thermo Scientific, Pittsburgh, 
PA), air- dried overnight, and stored at −20°C. For FISH 
analysis, all cases were investigated with in vitro diagnosis- 
certified probe sets targeting 1q21, del 17p13, del 13q14, 
and t(4;14) (Kreatech, Amsterdam, the Netherlands). 
Hybridization and signal detection were performed accord-
ing to the manufacturer’s protocols. Spot counting analysis 
was performed with an Olympus microscope (BX60, Tokyo, 
Japan). For each probe, 200 nuclei were evaluated. 
Frequencies of 20% (17p deletion) or 10% (all others) 
of cells were considered positive. Patients were categorized 
as high risk if they were positive for del 17p13, add 1q21, 
and/or t(4;14).
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EORTC quality of life questionnaire core 
module and multiple myeloma module
The European Organisation for Research and Treatment 
of Cancer (EORTC) quality of life questionnaire core 
module QLQ- C30 is a 30- item questionnaire that com-
prises nine multi- item scales measuring various dimen-
sions of HRQoL in patients with cancer [13]. The 
EORTC multiple myeloma module QLQ- MY20 is a 
20- item module that assesses symptoms/side effects 
and HRQoL issues specific to MM, and was designed 
for completion alongside the QLQ- C30 [14].
Both of these questionnaires were completed by obser-
vational study participants at baseline (before the start of 
study medication), after 3 and 6 months on treatment, 
and at the end of the study (1 month after the ninth 
treatment cycle). Patients completed the questionnaires 
unsupervised, at home. All responses were scored accord-
ing to the developers’ instructions.
Analysis of cell surface phenotype of T cells 
and natural killer cells by flow cytometry 
(phase 2 trial only)
For phenotypic characterization of T cells and natural killer 
(NK) cells, peripheral blood mononuclear cell (PBMC) 
samples were obtained at randomization and at three ran-
domly selected timepoints during treatment. The samples 
were analyzed by flow cytometry with panels including 
fluorochrome- conjugated monoclonal antibodies against 
the surface antigens, as described previously [15]. Briefly, 
all vitally frozen patient PBMCs were thawed, washed with 
cold fetal bovine serum (FBS), and resuspended in cold 
phosphate- buffered saline (PBS) supplemented with 2% 
FBS and 1 mmol/L ethylenediaminetetraacetic acid (EDTA). 
Antibody staining was performed as follows: Cells were 
washed once with PBS (containing 2% FBS and 1 mmol/L 
ethylenediaminetetraacetic acid [EDTA]) and incubated 
with antibody mixes at 4°C for 30 min. The labeled cells 
were then washed twice with PBS. Data acquisition was 
performed using a LSR II flow cytometer (Becton, Dickinson 
and Company) equipped with a high- throughput system. 
The data were analyzed by FACSDiva (BD Biosciences, 
San Jose, CA) and FlowJo X software (TreeStar Inc., Ashland 
OR). The CD3+CD14−CD19−CD56− population was used 
to identify T cells, while CD56+CD3−CD14- CD19− cells 
were defined as NK cells. Additionally, T cells were further 
subgrouped through CD45RA/CD45RO expression to 
 identify naïve/effector T cells and memory T cells, respec-
tively. Graphs were generated, and statistical analyses were 
performed by GraphPad Prism (GraphPad Software Inc. 
La Jolla, CA) and FlowJo X software (TreeStar Inc.).
Statistical analyses
Observational study
Observational study outcome parameters were defined as 
follows: OS, time from study inclusion at first relapse until 
death from any cause; PFS, time from inclusion until 
disease progression or death; TTP, time from inclusion 
until objective tumor progression. The primary endpoints 
were time to best response (TTR), PR, VGPR, and CR.
Phase 2 clinical trial
Phase 2 trial outcome parameters were defined as follows: 
OS, time from randomization until death from any cause; 
PFS, time from randomization until disease progression 
or death; and TTP, time from randomization until objec-
tive tumor progression. The primary objective was to 
compare the efficacy of prolonged treatment with Len 
versus Len+Dex, where efficacy was measured by median 
TTP within a 24- month timeframe. It was assumed that 
the mean difference in TTP between the two treatment 
groups should be zero, allowing for a lower equivalence 
bound of −8 months and an upper equivalence bound 
of 8 months, with an expected median TTP in the Len+Dex 
group of 18 months. For a significance level of 5%, a 
standard deviation of 10, and a power of 80%, it was 
calculated that 30 patients per treatment group would be 
sufficient (SAS version 9.2).
Statistical analyses were performed on the intention- to- 
treat population. For the phase 2 trial primary analysis, 
TTP was compared with Len versus Len+Dex using Kaplan–
Meier methodology and the log- rank test. The same methods 
were used for between- treatment PFS comparisons. 
Proportions of patients were compared using the chi- square 
test or, for low frequencies, Fisher’s exact test. Continuous 
variables were compared using Student’s t- test.
Quantification of the burden of prolonged treatment 
with Len versus Len+Dex was a secondary objective of 
the phase 2 trial. Between- group comparisons of the pro-
portion of patients reporting AEs were performed by 
chi- square test or, for low frequencies, Fisher’s exact test. 
Phase 2 trial AEs were “new- onset” AEs occurring after 
randomization. The safety analysis included data from all 
patients who received any study medication. The EORTC 
questionnaire results were compared at different timepoints 
using the chi- square test. For NK/T cell evaluations (phase 
2 trial), samples obtained during treatment were compared 
with those obtained at randomization using the unpaired 
t- test.
The data analyses reported in this manuscript were 
performed by J.L., E.H., and H.N. All authors had access 
to the primary clinical trial data.
2260 © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
J. Lund et al.Len vs. LenDex Maintenance after LenDex in 2nd Line
Role of the funding sources
Both studies reported in this manuscript were funded by 
research grants from Celgene Corporation and the Swedish 
Cancer Society. Celgene Corporation also paid for the ser-
vices of professional medical writers, who provided editorial 
assistance during the development of the manuscript. Neither 
of the funding sources contributed to the study design, 
nor to the collection, analysis, or interpretation of data.
Results
Patients and treatment
Between December 2010 and November 2013, 133 patients 
were enrolled into the observational study (Fig. S1). Sixty- 
two of these patients subsequently entered the phase 2 
trial and were randomized between June 2011 and February 
2014. At the cut- off date of March 31, 2016, the median 
(range) duration of follow- up of all 133 patients was 3.3 
(1.6–5) years. Baseline characteristics and first- line treat-
ments are summarized in Table 1. All patients had received 
only one prior line of treatment; 57% and 65% of patients 
in the observational study and phase 2 trial, respectively, 
had received high- dose chemotherapy plus autologous stem 
cell transplantation (ASCT), and 73% and 64%, respec-
tively, had been exposed to bortezomib and/or thalidomide. 
As shown in Table 1, the majority of patients had 
International Staging System (ISS) stage I or II disease 
at diagnosis; at randomization for the phase 2 trial, all 
patients had either stage I (63%) or stage II (38%) disease 
(data not shown). No patient had baseline creatinine 
clearance (CrCl) <15 mL/min, although baseline CrCl was 
<30 mL/min in two patients. In accordance with the 
product label, the Len dosage was reduced from 25 to 
5 mg/day in these two patients, neither of whom par-
ticipated in the phase 2 trial. Three patients enrolled in 
the phase 2 trial had dose reduction of Len to 15 mg 
in the phase 4 trial. Two of them continued on that dose 
in the phase 2 trial, and one had the dose restored to 
25 mg at the time of randomization. Median follow- up 
in both the observational study and the phase 2 trial was 
3 years (3.4 years for surviving patients).
In the observational study, median treatment duration 
from inclusion (excluding phase 2 trial treatment) was 
3.7 (range 0.2–9) months. Fifty- seven percent of obser-
vational study participants completed the planned number 
of treatment cycles; reasons for premature discontinuation 
were as follows: disease progression (16%); AEs or SAEs 
(16%); no response (8%); poor treatment adherence (2%); 
and withdrawal of consent (1%). Median treatment dura-
tion from randomization in the phase 2 trial was 12.2 
(range 0.7–48) months, with 35% of patients completing 
the maximum 24 treatment cycles. Reasons for premature 
discontinuation in the phase 2 trial were as follows: AEs/
SAEs (27%); disease progression (34%); withdrawal of 
consent (3%); and poor treatment adherence (1%).
Efficacy
Observational study
Median TTR and time to best response in the observa-
tional study (N = 133) were 1.7 (range 0.6–9.6) and 2.5 
(range 0.6–28) months. Rates of CR, VGPR, and PR fol-
lowing all treatments received in both this study and the 
phase 2 trial are summarized in Table 2. The median 
duration of response (DoR) among the total observational 
study population was 18.2 (range 1.6–57) months.
After 3.3 years median follow- up, median TTP in the 
total observational study population was 19.7 months (95% 
confidence interval [CI] 14.0–29.0; Fig. 1A). Twenty- eight 
percent (95% CI 20–37%) of patients were still on the original 
study medication at 3 years. PFS and OS rates at this time 
were 35% (95% CI 26–43%) and 61% (95% CI 52–69%; 
Fig. 1B), respectively, with disease progression being observed 
in 62% of patients. In the subgroup of patients who achieved 
≥PR in the observational study but did not enter the phase 
2 trial (n = 43), median TTP was 13.9 months (95% CI 
8.6–19.1) after 2.2 years’ median follow- up; 3- year PFS and 
OS were 19% (95% CI 8–34%) and 56% (95% CI 40–69%), 
respectively. The median DoR and response rate in this 
subpopulation were 9 months and 19%, respectively.
Phase 2 trial
After 26 months’ median follow- up, median TTP was 
24.9 months (12.5–not calculable) versus not reached with 
Len versus Len+Dex (Fig. 2A). Median TTP was not 
reached in the total phase 2 trial population (N = 62). 
Response rates at the time of randomization in the phase 
2 trial were as follows: CR, 2% (n = 1); VGPR, 10% 
(n = 10); and PR, 89% (n = 55). Responses deepened 
with continued treatment in 60% of phase 2 trial par-
ticipants. Of the 55 patients with a PR at randomization, 
26 subsequently achieved a VGPR and seven achieved a 
CR, while response deepened from an initial VGPR to a 
CR in four patients. Sixty- five percent of phase 2 trial 
participants achieved ≥VGPR as their best response (rates 
among patients randomized to Len versus Len+Dex were 
55% vs. 74%; P = not significant), including 19% CRs 
(16% vs. 23% randomized to Len vs. Len+Dex; P = not 
significant). The median DoR among all phase 2 trial 
participants was 26.4 months (range 5–57 months).
Three- year PFS and OS among phase 2 trial participants 
were 52% (95% CI 38–65%) and 73% (95% CI 60–83%), 
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Table 1. Baseline characteristics and the first- line treatment in the overall population included in the observational study and in the subpopulation of 
patients who proceeded into the phase 2 trial.
Observational study 
(N = 133)
Phase 2 trial Len 
(n = 31)
Phase 2 trial Len+Dex 
(n = 31) P
Median (range) age, years 67.5 (34.9–85.9) 65.0 (47.8–78.6) 67.2 (44.9–82.0) 0.284
 ≥75 year, n (%) 30 (23) 4 (13) 6 (19)
 <75 year, n (%) 103 (77) 27 (87) 25 (81)
Female/male sex, % 63/70 (47) 16/15 (52) 17/14 (55) 0.803
ECOG score, n (%)
 0 56 (43) 14 (45) 15 (48) 0.994
 1 53 (41) 12 (39) 13 (42)
 2 14 (11) 3 (10) –
 3 2 (2) – –
 Unknown 5 (4) 2 (6) 3 (10)
ISS disease stage at diagnosis, n (%)
 I 29 (22) 6 (19) 8 (26)
 II 52 (39) 16 (52) 11 (35)
 III 15 (11) 1 (3) 4 (13)
 Unknown 37(28) 8 (26) 8 (26)
M- component, n (%)
 IgA 27 (20) 0 5 (16) 0 7 (23) 0.721
 IgG 88 (66) 23 (74) 19 (61)
 IgM 1 (1) 0 (0) 0 (0)
 Bence Jones 6 (8) 0 3 (10) 2 (6)
 Unknown 11 (8) 0 (0) 0 3 (10)
Light chain type, n (%)
 Kappa 83 (62) 21 (68) 21 (68) 0.852
 Lambda 44 (33) 10 (32) 9 (29)
 Unknown 6 (5) 1 (2) 1 (3)
Hemoglobin, g/L
 Mean (SD) 115 (17) 116 (15) 118 (12) 0.681
 Median (range) 115 (63–155) 118 (90–143) 119 (84–138)
 Not available 3 0 0
Creatinine, μmol/L
 Mean (SD) 82 (31) 78 (20) 72 (23) 0.361
 Median (range) 75 (42–270) 75 (33–136) 68 (47–164)
 Not available 3 0 0
Albumin, g/L
 Mean (SD) 35.3 (4.4) 34.8 (6.9) 35.3 (3.1) 0.734
 Median (range) 36 (25–44) 36 (26–43) 35 (29–41)
 Not available 3 0 0
β2 microglobulin, mg/L
 Mean (SD) 3.5 (1.6) 2.3 (1.0) 2.3 (1.0) 0.484
 Median (range) 3.3 (1.5–7.7) 2.1 (1.6–5.3) 2.1 (1.0–5.2)
 Not available 96 11 11
Calcium, mmol/L
 Mean (SD) 2.34 (0.2) 2.18 (0.3) 2.15 (0.4) 0.774
 Median (min–max) 2.30 (1.90–3.98) 2.20 (2.04–2.68) 2.10 (2.04–2.70)
 Not available 27 0 0
Bone disease, n (%)
 No 24 (18) 3 (10) 6 (19) 0.322
 Yes 101 (76) 27 (83) 23 (75)
 Unknown 8 (6) 1 (3) 2 (6)
Prior ASCT, n (%) 76 (57) 20 (65) 20 (65) 0.739
Prior PI and/or immunomodulatory drug, n (%)
 Bortezomib 76 (57) 18 (58) 12 (39) 0.177
 Thalidomide 13 (10) 1 (3) 4 (13)
 Bortezomib + thalidomide 8 (6) 1 (3) 2 (6)
 Other 33 (25) 10 (33) 13 (42)
 Unknown 3 (2) 1 (3) 0 (0)
ASCT, autologous stem cell transplantation; ECOG indicates Eastern Cooperative Oncology Group; ISS, International Staging System; PI, proteasome 
inhibitor; SD, standard deviation.
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respectively—significantly higher than the corresponding 
values reported above for those patients who achieved ≥PR 
in the observational study but did not enter the phase 2 
trial (19% and 56%, respectively; P < 0.001 and P = 0.04). 
Three- year OS was 73% in both treatment arms (Fig. 2B). 
At the median follow- up time, the OS in the Len/Dex 
CR 85%, VGPR 81%, PR 50%, and PFS was CR 71%, 
VGPR 57%, PR 49%, for the Len group; Os Len CR 82%, 
VGPR 80%, PR 46%, PFS CR 57%, VGPR 40%, PR 36%.
The impact of cytogenetic abnormalities on progression 
and OS is shown in Table 3. In the populations of both 
Table 2. Summary of best treatment responses.
Response, n (%)
Observational study Phase 2 trial
All patients 
(N = 133)
Patients not entering  





OR 105 (79) 43 (61) 31 (100) 31 (100) 62 (100)
≥VGPR 55 (41) 15 (21) 17 (55) 23 (74) 40 (65)
CR 14 (11) 2 (3) 5 (16) 7 (23) 12 (19)
VGPR 41 (31) 13 (18) 12 (39) 16 (52) 28 (45)
PR 50 (38) 28 (39) 14 (45) 8 (26) 22 (35)
MR/SD 19 (14) 19 (27)
PD 4 (3) 4 (6)
NE 5 (4) 5 (7)
OR indicates overall response; CR, complete response; MR, minimal response; NE, not evaluable; PD, progressive disease; PR, partial response; SD, 
stable disease; VGPR, very good partial response.
Figure 1. Outcomes in the total observational study population 
(N = 133). (A) TTP measured from the time of inclusion in the study at 
first relapse. (B) OS measured from the time of inclusion in the study.
Figure 2. Outcomes in patients treated with Len (n = 31) versus 
Len+Dex (n = 31) in the phase 2 clinical trial. (A) TTP measured from 
randomization. Disease progression in the Len versus the Len+Dex arm 
was 47% (31–66%) versus 31% (17–52%) at 2 years, and 55% (38–
74%) versus 38% (22–61%) at 3 years (P = 0.14). (B) OS measured from 
randomization. Three- year OS was 73% in both treatment arms (95% 
CI 53–86% for Len+Dex, 53–85% for Len; P = 0.70).
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the observational study and the phase 2 trial, OS and the 
percentage of progression- free patients at 3 years were higher 
among patients with standard- versus high- risk profiles. 
Among the observational study population, all the inves-
tigated mutations except del(17p) significantly impacted the 
percentage of patients without progression, even with 60% 
threshold. By contrast, only del(13q) and t(4;14) significantly 
impacted OS. The OS of the treatment on subsequent 
relapse from both studies is summarized in Table 4.
EORTC quality of life questionnaires
Figure 3 summarizes the findings from the EORTC QLQ- 
C30 and EORTC QLQ- MY20 questionnaires, which were 
completed by observational study participants. No signifi-
cant differences were evident in any of the subscales over 
time. Insomnia increased during treatment (probably an 
effect of Dex) but declined to baseline at the end of 
treatment. Diarrhea also increased during treatment but 
failed to return to baseline by the end of the study, indi-
cating an increased time to normalize versus insomnia. 
Future perspective (MYFP) scores increased slightly during 
treatment and at the end of the study.
Safety
Table 5 summarizes treatment- emergent AEs (TEAEs). For 
phase 2 trial participants, TEAEs that occurred prior to 
randomization are included within the observational study 
data. The most common hematologic TEAEs during the 
observational study were thrombocytopenia (38%), anemia 
(30%), and neutropenia (13%). Febrile neutropenia was 
reported in only 2% of the observational study popula-
tion. Upper respiratory tract infection was the most com-
mon nonhematologic TEAE (15%). Thromboembolic 
events occurred in seven patients (5%).
The most common hematologic TEAE during the phase 
2 trial was neutropenia, which occurred in 89% of patients. 
However, the incidence of febrile neutropenia remained 
low (2%). Diarrhea was more common in the phase 2 
trial than in the observational study, suggesting that this 
AE may increase with prolonged Len administration. Four 
patients developed cataracts during this trial—two in each 
treatment arm. Pneumonia was more common with 
Len+Dex than with Len; however, TEAE rates overall were 
similar in the two treatment arms.
Serious adverse events
In total, 81 SAEs were reported across the two studies. 
The most common SAE was pneumonia, occurring in 15 
patients; 11 of these cases were recorded during the obser-
vational study. Overall, nine- second primary malignancies 
(SPMs) were reported in nine patients (7%), although only 
two occurred during the studies: one anal adenocarcinoma, 
which occurred in a patient in the Len+Dex arm in the 
phase 2 trial and was confirmed after 14 months of treat-
ment; and one non- small- cell lung carcinoma, which devel-
oped within 2 months of treatment in an observational 
Table 4. The OS of the treatment on subsequent relapse.
n (%) Median, years At 2, % (P)1
Bortezomib- based 43 (57) 2.0 50 (NS)
Thalidomide- based 6 (8) 1.4 0 (NS)
Lenalidomide- based 14 (19) NR 58 (NS)
Other 12 (16) 2.4 50 (NS)
1P- values are for the comparison of patients with versus without borte-
zomib treatment.
Table 3. Cytogenetic abnormalities detected by FISH.
n (%)
Patients with progression (%) Overall survival (%)
At 2 years At 3 years (P)1 At 2 years At 3 years (P)1
Observational study
 +1q21 28 (35) 75 79 68 55
 No +1q21 52 (65) 44 53 (0.006) 77 73 (0.253)
 del(13q) 25 (31) 80 80 56 48
 No del(13q) 56 (69) 41 52 (0.005) 84 78 (0.008)
 del(17p) 8 (10) 75 – 75 50
 No del(17p) 73 (90) 50 57 (0.09) 75 71 (0.12)
 t(4;14) 7 (15) 0 (median=8 months) 0 (median=5 months) 14 0 (median=21 months)
 No t(4;14) 41 (85) 45 55 (0.0001) 83 75 (<0.001)
 High risk 37 (45) 73 81 67 55
 Standard risk 45 (55) 38 46 (0.001) 80 78 (0.07)
Phase 2 trial
 High risk 20 (50) 57 70 75 65
 Standard risk 20 (50) 15 25 (0.009) 90 90 (0.14)
1P- values are for the comparison of patients with versus without the specified abnormality or risk factor.
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Figure 3. Results from the EORTC quality of life questionnaires, presented as mean and 95% confidence intervals. (A) Results from the core module, 
EORTC QLQ- C30. (i) physical functioning (PF2), role functioning (RF2), emotional functioning (EF), cognitive functioning (CF); (ii) social functioning 
(SF), global health (QL2), fatigue (FA), pain (PA); (iii) nausea and vomiting (NV), dyspnoea (DY), insomnia (SL), appetite loss (AP); (iv) constipation (CO), 
diarrhea (DI), and financial difficulties (FI). (B) Results from the multiple myeloma module, EORTC QLQ- MY20: future perspective (MYFP), body image 
(MYBI), disease symptoms (MYDS), and side effects of treatment (MYSE). BL indicates baseline (n = 105); 3 m, at 3 months of treatment (n = 61); 6 m, 
at 6 months of treatment (n = 22); EoT, end of trial (1 month after the ninth cycle; n = 38).
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study participant. Two of the nine SPMs were hematologic, 
both occurring in the phase 2 trial: one large B- cell lym-
phoma in a Len+Dex recipient and one acute myeloid 
leukemia in a single- agent Len recipient. Both patients had 
received high- dose melphalan during first- line treatment. 
The remaining SPMs were as follows: pancreatic cancer 
(n = 1); lung cancer (n = 1); adenocarcinoma of the bowel 
(n = 2); and basal cell skin cancer (n = 1). Four deaths 
(3%) occurred during the observational study (Fig. S1): 
one owing to progressive disease; one owing to lung cancer; 
and two as a result of infectious disease complications 
(pneumonia and sepsis of unknown origin). One patient 
(2%) died during the phase 2 trial (cause “sudden death”; 
no autopsy was performed).
Flow cytometry characterization of 
peripheral blood mononuclear cells (phase 2 
trial)
To investigate the impact of Len versus Len+Dex on T 
and NK cells, we carried out a comparative analysis of 
these two cell types. PBMC samples from 11 and nine 
Len and Len+Dex recipients, respectively, were collected 
at randomization and at random timepoints during 
treatment. Neither the percentage of NK cells nor the 
expression levels of activating receptors and inhibitory 
receptors differed significantly either between patients 
treated with Len and Len+Dex or during treatment versus 
at trial inclusion (Fig. S2). Importantly, we observed no 
differences in cell surface expression levels of CD16 or 
NKG2D molecules, which have previously been shown to 
be positively impacted by treatment with Len, as previ-
ously described[16].
Further to the above, analyses of T cells and their subsets 
(memory and naïve), as well as expression levels of costimu-
lation, exhaustion, and energy- related proteins, indicated no 
significant differences between patients treated with Len and 
Len+Dex (Fig. S3). Finally, molecules such as CD16, NKG2D, 
and CD28, which are essential for the control and elimina-
tion of myeloma, were highly expressed in all the patient 
material analyzed, indicating that neither Len nor Len+Dex 
prolonged treatment at first relapse reduces either the expres-
sion or, potentially, the activity of these cells [16–19].
Discussion
In the two studies reported here, OS did not differ in 
patients with RRMM who received Len versus Len+Dex 





Len (n = 31) Len+Dex (n = 31) Total population (N = 62)
All grades,  
n (%)















Grade 3–4,  
n (%)
Fatigue 13 (10) 0 (0) 6 (19) 0 (0) 6 (19) 0 (0) 12 (19) 0 (0)
Nausea 3 (2) 0 (0) 3 (10) 0 (0) 3 (10) 0 (0) 6 (10) 0 (0)
Anemia 40 (30) 5 (4) 9 (29) 0 (0) 6 (19) 0 (0) 15 (24) 0 (0)
Thrombocytopenia 50 (38) 7 (5) 20 (65) 1 (3) 16 (52) 1 (3) 36 (58) 2 (3)
Neutropenia 17 (13) 4 (3) 29 (94) 20 (65) 26 (84) 9 (29) 55 (89) 29 (47)
Febrile neutropenia 2 (2) 1 (1) 0 (0) 0 (0) 1 (3) 1 (3) 1 (2) 1 (2)
Pneumonia 15 (11) 9 (7) 1 (3) 0 (0) 5 (16) 3 (10) 6 (10) 3 (5)
Herpes zoster 
infection1
6 (5) 1 (1) 0 (0) 0 (0) 2 (6) 1 (3) 2 (3) 1 (2)
Upper respiratory 
tract infection
20 (15) 2 (2) 10 (32) 0 (0) 8 (26) 0 (0) 18 (29) 0 (0)
Cough 4 (3) 0 (0) 2 (6) 0 (0) 1 (3) 0 (0) 3 (5) 0 (0)
Urinary tract infection 5 (4) 1 (1) 1 (3) 0 (0) 2 (6) 0 (0) 3 (5) 0 (0)
Diarrhea 4 (3) 0 (0) 9 (29) 0 (0) 8 (26) 1 (3) 17 (27) 1 (2)
Constipation 9 (7) 1 (1) 3 (10) 0 (0) 1 (3) 1 (3) 4 (6) 1 (2)
Deep vein 
thrombosis2
3 (2) 0 (0) 2 (6) 1 (3) 1 (3) 1 (3) 3 (5) 2 (3)
Pulmonary 
embolism2
4 (3) 3 (2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Back pain 3 (2) 1 (1) 7 (23) 0 (0) 3 (10) 0 (0) 10 (16) 0 (0)
Cataract 0 (0) 0 (0) 2 (6) 0 (0) 2 (6) 1 (3) 3 (5) 1 (2)
1No prophylaxis against herpes zoster virus was used.
2All participants were given prophylaxis with LMWH or ASA according to standard procedures at each clinic.
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as maintenance therapy following a response to initial 
Len+Dex treatment at first relapse. Although there was 
an apparent trend toward increased TTP in the Len+Dex 
arm, this did not reach statistical significance. Additionally, 
we observed no significant differences in the phenotype 
of circulating lymphocytes including cytotoxic T cells, 
helper T cells, and NK cells among Len versus Len+Dex 
recipients, and previous studies demonstrated that con-
comitant treatment with either low- (160 mg/cycle) or 
high- dose (480 mg/cycle) Dex may result in inhibition 
of the immunomodulatory effects of Len [20, 21]. In 
these studies, Dex treatment also reduced the expression 
of activating receptors such as NKG2D in NK cells. In 
contrast, we observed no changes in the levels of expres-
sion of these activating molecules following treatment 
with either Len or Len+Dex in our phase 2 clinical trial. 
One potential explanation for these differing results could 
be that all the patients in our phase 2 trial had already 
responded to Len+Dex in the preceding observational 
study, and therefore were able to tolerate the immuno-
suppressive effects of Dex. Our results do not exclude 
the possibility that Len+Dex may prolong TTP versus 
Len alone, but this is unconfirmed and must be balanced 
against the potential increased risk of AEs with Len+Dex.
In Europe, Len plus low- dose Dex is the standard treat-
ment for MM at first relapse; it is also becoming estab-
lished as a standard therapeutic option for newly diagnosed 
MM in patients who are ineligible for ASCT. As all the 
participants in our observational study had received only 
one prior line of treatment, the results obtained confirm 
the efficacy of Len+Dex as a first- line treatment for RRMM.
Our results are broadly consistent with those of previ-
ous studies, although differing study methods and patient 
populations confound direct comparison. In transplant- 
ineligible patients with newly diagnosed MM in the FIRST 
trial, median PFS was prolonged with Len+Dex mainte-
nance administered continuously until disease progression 
(25.5 months) versus Len+Dex administered for a fixed 
period of 18 months (20.7 months) or melphalan–pred-
nisone–thalidomide administered for 18 months 
(21.2 months) [22]. The 3- year PFS rate with continued 
Len+Dex was ~40% [22]. In our phase 2 trial, median 
PFS had not been reached at 3 years in patients who 
received prolonged therapy with Len+Dex following a 
response to initial Len+Dex treatment, and the PFS rate 
was 60%. Corresponding values in the subgroup of patients 
who responded to initial treatment but did not enter the 
phase 2 study were 13.9 months and 19%. In two ran-
domized trials that included continuous Len+Dex as a 
control arm (the ASPIRE study [23] [carfilzomib plus 
Len+Dex vs. Len+Dex] and TOURMALINE- MM1 [24] 
[ixazomib plus Len+Dex vs. Len+Dex] trials, both per-
formed in patients with MM who had received 1–3 prior 
therapies), median PFS with Len+Dex was 17.6 months 
and 14.7 months, respectively. Our data suggest that con-
tinuous Len+Dex improves outcome vs. fixed- duration 
therapy, but limitations in the studies prevent us from 
drawing this conclusion.
Another major determinant of treatment outcome is 
the presence or absence of high- risk cytogenetic aberra-
tions. Rates of disease progression (based on TTP, rather 
than PFS, data) in our observational study were nearly 
doubled at 3 years in patients with versus those without 
high- risk cytogenetic features and were increased nearly 
threefold in the phase 2 trial, while 3- year OS rates in 
patients with high- risk cytogenetics were reduced by nearly 
30% versus standard- risk patients in both studies. Forty- 
five percent and 50% of patients in the observational 
study and the phase 2 trial, respectively, had high- risk 
cytogenetic features.
Regarding safety, the hematologic TEAEs neutropenia 
and thrombocytopenia were more common with prolonged 
(phase 2 trial) versus short- term (observational study) 
Len+Dex treatment. However, these events were managed 
successfully: Neutropenia was treated with granulocyte 
colony- stimulating factor, while thrombocytopenia was 
managed with occasional discontinuation of anticoagulants. 
Rates of febrile neutropenia were similar in the two stud-
ies. The overall pattern of AEs in our studies was consist-
ent with that observed in previous studies, in which 
neutropenia was also reported as the most common grade 
3–4 AE with either Len or Len+Dex [6, 8–10]. The longer 
duration of treatment in the phase 2 trial had little impact 
on the rates of grade 3–4 AEs, with the exception of 
neutropenia. Comparison of TEAEs in the two arms of 
the phase 2 trial suggests that Len and Len+Dex were 
similarly well tolerated. However, patient numbers were 
relatively small, and it remains possible that treatment 
with Len+Dex could place patients at increased overall 
risk of TEAEs. With prolonged treatment, one should 
also consider the risk of second primary malignancies 
(SPM) associated with Len. We observed a total of nine 
SPMs (7%) during the study and the follow- up time. 
This risk must always be compared with the putative 
benefits from the drug.
Our studies had some limitations. As the first study 
was observational, the data were not fully comprehensive—
for example, β2- microglobulin levels were not available. 
There was no lower limit for CrCl; however, only two 
patients had CrCl <30 mL/min at baseline, and no patient 
had CrCl <15 mL/min. Therefore, the applicability of our 
results to patients with renal impairment is uncertain. As 
the phase 2 trial was initiated in 2010, measurement of 
minimal residual disease was not included in the protocol. 
The majority of patients had ISS stage I or II disease, 
making it impossible to stratify the results by ISS stage.
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In conclusion, our results indicate that long- term (up 
to 24 months) prolonged treatment with Len with or 
without Dex provides sustained, clinically relevant 
responses. The longer duration of treatment in the phase 
2 trial was associated with increased, but manageable, 
AEs beside the SPMs. After achievement of a response 
to initial Len+Dex treatment, OS did not differ between 
patients subsequently treated with Len and Len+Dex at 
either 2 or 3 years. There was a trend toward prolonged 
TTP with Len+Dex versus Len, but this did not reach 
statistical significance and, when selecting the most appro-
priate treatment, possible benefits must be balanced against 
the potential risk of AEs. There was a clear trend toward 
increased depth of response and PFS with Len- Dex over 
Len. A larger study may have met statistical 
significance.
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